造影剂肾病预防的研究进展

Abstract
Figure/Table
References (36)
Related Citation (2)

Download: PDF (623 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract With the development of medical imaging and interventional diagnosis and treatment technology, the use of contrast agent is more and more extensive. The resulting incidence and mortality of contrast nephropathy are also increasing. It has become the third major cause of iatrogenic acute kidney injury. There is no effective treatment for contrast nephropathy, so prevention is very important. Currently, the main preventive measures include identification of high-risk groups of contrast nephropathy, selection of contrast agents, remote ischemic preconditioning, and prevention of related drugs such as water chemotherapy, alkalization therapy, antioxidants, vasodilators, etc. However, most preventive measures are still controversial and need further study and discussion. This article will focus on the preventive measures of contrast nephropathy.

Key words： Contrast-induced nephropathy Contrast agent Drug prevention Remote ischemic preconditioning

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Mengqing1 CAO Changchun1 WAN Xin2

Cite this article:

MA Mengqing1 CAO Changchun1 WAN Xin2. Reserch advances in the prevention of contrast nephropathy[J]. 中国医药导报, 2019, 16(27): 49-52.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I27/49

[1] Fahling M，Seeliger E，Patzak A，et al. Understanding and preventing contrast-induced acute kidney injury [J]. Nat Rev Nephrol，2017，13（3）：169-180.
[2] Aksu U，Gulcu O，Aksakal E，et al. Long-Term Mortality and Contrast-Induced Nephropathy [J]. Angiology，2019， 70（8）：783.
[3] Briasoulis A，Pala M，Telila T，et al. Statins and contrast-induced nephropathy：a systematic review and meta-analysis [J] Curr Pharm Des，2017，23.
[4] Mamoulakis C，Tsarouhas K，Fragkiadoulaki I，et al. Contrast-induced nephropathy：Basic concepts，pathophysiological implications and prevention strategies [J]. Pharmacol Ther，2017，180：99-112.
[5] Liu Y，Liu YH，Chen JY，et al. A simple pre-procedural risk score for contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention [J]. Int J Cardiol，2015，180：69-71.
[6] Chen YL，Fu NK，Xu J，et al. A simple preprocedural score for risk of contrast-induced acute kidney injury after percutaneous coronary intervention [J]. Catheter Cardiovasc Interv，2014，83（1）：E8-E16.
[7] Barrett BJ，Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media [J]. Radiology，1993，188（1）：171-178.
[8] 李鸿波，刘波，刘敏.碘克沙醇和碘普罗胺对2型糖尿病患者肾功能影响的临床观察[J].药物流行病学杂志，2017，26（2）：92-94，105.
[9] Eng J，Wilson RF，Subramaniam RM，et al. Comparative Effect of Contrast Media Type on the Incidence of Contrast-Induced Nephropathy：A Systematic Review and Meta-analysis [J]. Ann Intern Med，2016，164（6）：417-424.
[10] Mehran R，Aymong ED，Nikolsky E，et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention：development and initial validation [J]. J Am Coll Cardiol，2004，44（7）：1393-1399.
[11] Bucher AM，De Cecco CN，Schoepf UJ，et al. Is contrast medium osmolality a causal factor for contrast-induced nephropathy? [J]. Biomed Res Int，2014，2014：931413.
[12] Stacul F，van der Molen AJ，Reimer P，et al. Contrast induced nephropathy：updated ESUR Contrast Media Safety Committee guidelines [J]. Eur Radiol，2011，21（12）：2527-2541.
[13] Cheungpasitporn W，Thongprayoon C，Brabec BA，et al. Oral hydration for prevention of contrast-induced acute kidney injury in elective radiological procedures：a systematic review and meta-analysis of randomized controlled trials [J]. N Am J Med Sci，2014，6（12）：618-624.
[14] Pakfetrat M，Malekmakan L，Salmanpour Z，et al. Comparison of Normal Saline，Ringer′s Lactate，and Sodium Bicarbonate for Prevention of Contrast-induced Nephropathy in Patients with Coronary Angiography：A Randomized Double-blind Clinical Trial [J]. Indian J Nephrol，2019，29（1）：22-27.
[15] Zhang B，Liang L，Chen W，et al. The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency：a meta-analysis [J]. BMJ Open，2015，5（3）：e006989.
[16] Abouzeid S，Mosbah O. Evaluation of different sodium bicarbonate regimens for the prevention of contrast medium-induced nephropathy [J]. Electron Physician，2016，8（2）：1973-1977.
[17] Park SH，Jeong MH，Park IH，et al. Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention [J]. Int J Cardiol，2016，212：100-106.
[18] Schafer FQ，Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple [J]. Free Radic Biol Med，2001， 30（11）：1191-1212.
[19] Alencar JL，Lobysheva I，Geffard M，et al. Role of S-nitrosation of cysteine residues in long-lasting inhibitory effect of nitric oxide on arterial tone [J]. Mol Pharmacol，2003，63（5）：1148-1158.
[20] Kang X，Hu DY，Li CB，et al. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes：a systematic review and meta-analysis [J]. Ren Fail，2015，37（10）：297-303.
[21] Stacul F，van der Molen AJ，Reimer P，et al. Contrast induced nephropathy：updated ESUR Contrast Media Safety Committee guidelines [J]. Eur Radiol，2011，21（12）：2527-2541.
[22] Agarwal R. Statin induced proteinuria：renal injury or renoprotection? [J] J Am Soc Nephrol，2004，15（9）：2502-2503.
[23] Han Y，Zhu G，Han L，et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease [J]. J Am Coll Cardiol，2014，63（1）：62-70.
[24] Liang M，Yang S，Fu N. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy：A meta-analysis of 15 randomized controlled trials [J]. Medicine （Baltimore），2017，96（27）：e7384.
[25] Liu X，Hang Y，Shen L，et al. Prevention of contrast-induced nephropathy with prostaglandin E1 in patients undergoing percutaneous coronary procedures：A meta-analysis of 24 randomized controlled trials [J]. Clin Nephrol，2018，90（5）：313-324.
[26] Do?覥egowska B，Piku?覥a E，Safranow K，et al. Metabolism of eicosanoids and their action on renal function during ischaemia and reperfusion：the effect of alprostadil [J]. Prostaglandins Leukot Essent Fatty Acids，2006，75（6）：403-411.
[27] Li WH，Li DY，Qian WH，et al. Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention [J]. Int Urol Nephrol，2014，46（47）：781-786.
[28] Miao Y，Zhong Y，Yan H，et al. Alprostadil plays a protective role in contrast-induced nephropathy in the elderly [J]. Int Urol Nephrol，2013，45（4）：1179-1185.
[29] Arabmomeni M，Najafian J，Abdar Esfahani M，et al. Comparison between theophylline，N-acetylcysteine，and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy [J]. ARYA Atheroscler，2015，11（1）：43-49.
[30] Dai B，Liu Y，Fu L，et al. Effect of theophylline on prevention of contrast-induced acute kidney injury：a meta-analysis of randomized controlled trials [J]. Am J Kidney Dis，2012，60（3）：360-370.
[31] Sahin I，Gungor B，Can MM，et al. Lower blood vitamin D levels are associated with an increased incidence of contrast-induced nephropathy in patients undergoing coronary angiography [J]. Can J Cardiol，2014，30（4）：428-433.
[32] Zhang MM，Lv QZ，Li XY. Drug Effects and Clinical Investigations for Contrast-Induced Nephropathy After Coronary Angiography or Percutaneous Coronary Intervention in Patients With Diabetes [J]. Am J Ther，2017， 24（4）：e423-e430.
[33] Wong PC，Guo J，Zhang A. A hypothesis on the conflicting results of angiotensin converting enzyme inhibitor in the prevention of contrast-induced nephropathy [J]. Med Hypotheses，2015，85（6）：874-877.
[34] Wang F，Yin J，Lu Z，et al. Limb ischemic preconditioning protects against contrast-induced nephropathy via renalase [J]. EBioMedicine，2016，9：356-365.
[35] Hu J，Jia P，Ding X，et al. Protection of remote ischemic preconditioning against acute kidney injury：a systematic review and meta-analysis [J]. Crit Care，2016，20（1）：111.
[36] Zhou F，Song W，Wang Z，et al. Effects of remote ischemic preconditioning on contrast induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome [J]. Medicine （Baltimore），2018， 97（2）：e9579.